tbuckley/cabot-search huggingface dataset:
Genetic Mutation and Outcome of Venetoclax-Based Therapy in Newly Diagnosed AML in the Real World: Hokkaido Leukemia Net Study
Authors: Naoki Miyashita, Masahiro Onozawa, Jun Nagai, Shota Yoshida, Hiroyuki Kimura, Toshihiro Matsukawa, Shinsuke Hirabayashi, Akio Mori, Takeshi Kondo, Daisuke Hidaka, Koichiro Minauchi, Akio Shigematsu, Junichi Hashiguchi, Tetsuyuki Igarashi, Yasutaka Kakinoki, Yutaka Tsutsumi, Hiroshi Iwasaki, Shota Yokoyama, Kentaro Wakasa, Katsuya Fujimoto, Toshimichi Ishihara, Hajime Sakai, Satoshi Iyama, Tatsuo Oyake, Takanori Teshima
Journal: Blood (2023)
Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders
Authors: Agnese Mattei, Giovanni Marconi, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Claudio Cerchione, Irene Zacheo, Maria Benedetta Giannini, Marianna Norata, Giovanni Martinelli, Anna Ferrari, Maria Teresa Bochicchio, Martina Ghetti, Matteo Marchesini, Giorgia Simonetti, Gerardo Musuraca, Davide Nappi
Journal: Blood (2023)
Azacitidine for Injection Combined with Chidamide in Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase I Study
Authors: Jingwei Yu, Yaxiao Lu, Yixin Yao, Xianming Liu, Lanfang Li, Zhengzi Qian, Lihua Qiu, Shiyong Zhou, Xianhuo Wang, Huilai Zhang
Journal: Blood (2023)
A Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Relapsed and / or Refractory Myeloma: A Report from the Asian Myeloma Network
Authors: Wei-Ying Jen, Melissa Ooi, Sanjay De Mel, Cinnie Soekojo, Sung-Soo Yoon, Xinhua Li, Neha Awasthi, Sarah M Burkill, Brian GM Durie, Wee-Joo Chng
Journal: Blood (2023)
MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study
Authors: Moritz Furstenau, Adam Giza, Christof Schneider, Eugen Tausch, Sandra Robrecht, Matthias Ritgen, Jörg Bittenbring, Holger F. Hebart, Björn Schöttker, Anna Lena Illert, Ullrich Graeven, Andrea Stoltefuss, Bernhard Heinrich, Robert Eckert, Anna-Maria Fink, Janina Stumpf, Florian Simon, Kirsten Fischer, Othman Al-Sawaf, Petra Langerbeins, Fanni Kleinert, Jonathan Weiss, Karl-Anton Kreuzer, Anke Schilhabel, Monika Brüggemann, Barbara F. Eichhorst, Stephan Stilgenbauer, Michael Hallek, Paula Cramer
Journal: Blood (2023)
Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting
Authors: Andrew J Portuguese, Aya Albittar, Emily C Liang, Jennifer J. Huang, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Hans-Peter Kiem, Filippo Milano, Aude G Chapuis, Folashade Otegbeye, Ryan D Cassaday, David G Maloney, Jordan Gauthier
Journal: Blood (2023)
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Authors: Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J. Harrison, Nieves Lopez-Muñoz
Journal: Blood (2023)
<i>Hnrnpu</i> mutations Are Haploinsufficient and Alter the Transcriptome of MYC-Driven Lymphomas
Authors: Qurat Ul Ain Qureshi, Krysta Mila Coyle, Nicole Thomas, Brett Collinge, Kostiantyn Dreval, Laura Hilton, Jasper Wong, David W. Scott, Timothy Audas, Ryan Morin
Journal: Blood (2023)
Comparative Study for Haplo, MSD and MUD Allo-Hcts for Core-Binding Factor AML Patients in CR2: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Authors: Yishan Ye, Myriam Labopin, Gerard Socié, Ibrahim Yakoub-Agha, Igor Wolfgang Blau, Mahmoud Aljurf, Édouard Forcade, Tobias Gedde-Dahl, David Burns, Jan Vydra, Khaled Halahleh, Rose-Marie Hamladji, Ali Bazarbachi, Eolia Brissot, Arnon Nagler, Lin Li, Yi Luo, Yanmin Zhao, Fabio Ciceri, He Huang, Mohamad Mohty, Norbert Claude Gorin
Journal: Blood (2023)
Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma
Authors: Sabrina L. Browning, Allison J. Li, Terri L. Parker, Noffar Bar, Tara Anderson, Erica Stevens, Yuxin Liu, Martin Matthews, Jennifer VanOudenhove, Rebecca Cardone, Qiushi Sun, Robert Hale, Stephanie Halene, Richard Kibbey, Natalia Neparidze
Journal: Blood (2023)
Bone Marrow, Laboratory, and Clinical Features in Pediatric Patients with <i>RUNX1</i> Familial Platelet Disorder with Associated Myeloid Malignancy (FPDMM)
Authors: Seila De Leon, Michelly Sampaio De Melo, Nisha Patel, Alina Dulau Florea, Irina Maric, Raul C. Braylan, Weixin Wang, Matthew Merguerian, Elizabeth J. Andrews, Lea Cunningham, David J. Young, Shawn Chong, Natalie Deuitch, Joie Davis, Kathleen Craft, Theo Heller, Pamela Frischmeyer-Guerrerio, Paul Pu Liu, Katherine R. Calvo
Journal: Blood (2023)
A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Authors: Jae H. Park, Maria Lia Palomba, Sean M. Devlin, Yannis K. Valtis, Devanjan S Sikder, Brigitte Senechal, Xiuyan Wang, Elizabeth Cathcart, Kelly Liotta, Alina Yu, Kelsey Stocker, Honglei Zhang, Heiko Schoder, Doris Leithner, Jia Li, Leopold Sellner, Jorge Mansilla-Soto, Isabelle Riviere, Michel Sadelain
Journal: Blood (2023)
Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis
Authors: Georg Hess, Vladan Vucinic, Kai Rejeski, Enver Aydilek, Linda Simon, Olaf Penack, Christian Koenecke, Malte von Bonin, Bastian von Tresckow, Martin Fehr, Christiane Pott, Stephan Stilgenbauer, Corinna Leng, Roland Schroers, Johannes Duell, Reinhard Marks, Fabian Mueller, Uta Brunnberg, Andrea Kerkhoff, Anke Ohler, Eva-Maria Wagner Drouet, Irene Schmidtmann, Matthias Theobald, Martin Dreyling, Peter Dreger
Journal: Blood (2023)
Patient Characteristics and Outcomes of Sinusoidal Obstruction Syndrome with and without Hematopoietic Stem Cell Transplant
Authors: Suma Sri Chennapragada, Vaishnavi Singh, Shriya Goyal, Saloni Savani, Sindhu Thevuthasan, Kamleshun Ramphul, Shivani Sharma, Arcita Hanjani Pramudita, Hemamalini Sakthivel, Samip Master
Journal: Blood (2023)
Levels of Individual Mid and Long Chain Polyunsaturated Triacylglycerols (TAGs) Are Different between the Bone Marrow Microenvironment of Patients with Multiple Myeloma (MM) and Monoclonal Gammopathy of Unknown Significance (MGUS)
Authors: Yogesh Chawla, Emilie Anderson, Isas Rosario Vasquez, Rachel A Simon, Taro Hitosugi, Shaji Kunnathu Kumar, Wilson I. Gonsalves
Journal: Blood (2023)
Aberrant Activity of the Calcium Sensor STIM1 Underlies Congenital Platelet Disorders and Myeloproliferative Neoplasms
Authors: Molly Brakhane, Vittorio Abbonante, Angelo B. A. Laranjeira, Christian Di Buduo, Brooke Sadler, Katrina Ashworth, Tim Kong, Fan He, Mary C. Fulbright, Dong Chen, Regina Clemens, Elena Pegoraro, Michele P. Lambert, Kandace Gollomp, Jorge Di Paola, Alessandra Balduini, Stephen T. Oh
Journal: Blood (2023)
Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study
Authors: Lucía Pérez-Lamas, Adrian Segura Diaz, Elvira Mora, Marta Hidalgo Soto, Antonio Paz Coll, Natalia De Las Heras, Montse Cortes, Patricia Velez Tenza, Magdalena Sierra Pacho, María Alicia Senin, Anna Angona, Carlos Cervero, Raquel De Paz Arias, Araceli Salamanca Cuenca, Marta Santaliestra, Javier López Marin, Luis Felipe Casado Montero, Valentín García Gutiérrez
Journal: Blood (2023)
Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study
Authors: Claire N Harrison, Alessandro Maria Vannucchi, Christian Recher, Francesco Passamonti, Aaron T. Gerds, Juan Carlos Hernandez Boluda, Abdulraheem Yacoub, Shireen Sirhan, Jun Kawashima, Bharat Patel, Bryan Strouse, Uwe Platzbecker
Journal: Blood (2023)
Clinical and Laboratory Indications for Serum Protein Electrophoresis Testing in US Veterans: A Retrospective Cohort Study
Authors: Niharika Pant, Lawrence Liu, Mei Wang, Nikhil Grandhi, Theodore Thomas, Kristen M. Sanfilippo, Graham Colditz, Daphne R Friedman, Martin William Schoen, Su-Hsin Chang
Journal: Blood (2023)
High Rates of Thrombotic Events in Newly Diagnosed Multiple Myeloma Patients Enrolled on the Maia Trial
Authors: Sterling Rosqvist, Victoria A. Vardell, Eric Anto, Gliceida Galarza Fortuna, Douglas Peters, Charlotte B Wagner, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Michael R. Savona, Kelley Julian, Brian McClune, Ghulam Rehman Mohyuddin, Amandeep Godara, Muhamed Baljevic, Douglas Sborov
Journal: Blood (2023)
Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia
Authors: Jordi Ribera, Mireia Morgades, Isabel Granada, Teresa González, Ricardo Sánchez, Rosa Ayala, Esperanza Such, Gayane Avetisyan, Susana Barrera, Beatriz Soriano, Anna Torrent, Cristina Gil, Carmen Botella, Clara Maluquer Artigal, Pere Barba, Pau Montesinos, José González-Campos, Pilar Martínez-Sánchez, Rosa Coll, Jordi Esteve, Maria Rocio Benito Sanchez, Thaysa Lopes, Celia González Gil, Eulàlia Genescà, Joaquin Martínez-López, Jesús María Hernández-Rivas, Alberto Orfao, Josep-Maria Ribera
Journal: Blood (2023)
Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials
Authors: Ruben A. Mesa, Andrew C. Perkins, Yeow Tee Goh, Maria Laura Fox, Donal P McLornan, Jeanne Palmer, Lynda Foltz, Alessandro Maria Vannucchi, Steffen Koschmieder, Francesco Passamonti, Sung-Eun Lee, Jun Kawashima, Bryan Strouse, Francisco Gonzalez Carreras, Stephen T. Oh
Journal: Blood (2023)
Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
Authors: Madhav V. Dhodapkar, Melissa Alsina, Jesus G. Berdeja, Krina K. Patel, Shambavi Richard, Ravi Vij, Xavier Leleu, Daniel N. Egan, P. Leif Bergsagel, Ran Reshef, Saad Z Usmani, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Laurie Eliason, Xiaobo Zhong, Chiara Greggio, Sinhan Tran, Maria Chaudhry, Marlene J. Carrasco-Alfonso, David S. Siegel
Journal: Blood (2023)
Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: The Rectangle Trial
Authors: Diego Villa, Jean-Francois Larouche, Matthew C. Cheung, Mary-Margaret Keating, Katherine Zukotynski, Petter Tonseth, Samantha Mayo, Robert Laister, David W. Scott, John Kuruvilla
Journal: Blood (2023)
Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients
Authors: Anita Sarma, Charlotte Evans, Surita Dalal, Nichola Webster, Andy Rawstron, Jane Shingles, Darren Newton, David Allan Cairns, Paul Glover, Thomas Grand, Helen Warren, Sue Bell, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen
Journal: Blood (2023)
Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL
Authors: Sanfang Tu, Lijuan Zhou, Rui Huang, Yanjie He, Xuan Zhou, Jilong Yang, Yuxing Hu, Honghao Zhang, Lung-Ji Chang, Yuhua Li
Journal: Blood (2023)
Sting-Mediated Interferon Signaling Exerts Potent Antileukemic Effects in High-Risk Myeloid and Monocytic Malignancies
Authors: Yue Wei, Ziyi Li, Hui Yang, Hong Zheng, Vicky Appleman, Tiquella Hatten, Yu-Chung Huang, Jeffrey Raizer, Alex Parent, Neil Lineberry, Guillermo Garcia-Manero, Guillermo Montalban-Bravo
Journal: Blood (2023)
Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial
Authors: Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodriguez Otero
Journal: Blood (2023)
Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men
Authors: Ola Bratt, Rebecka Arnsrud Godtman, Thomas Jiborn, Jonas Wallström, Olof Akre, Stefan Carlsson, Tobias Nordström, Erik Thimansson, Max Alterbeck, Sophia Zackrisson, Jonas Hugosson, Anders Bjartell, Anna Lantz
Journal: European Urology (2023)

The European Union recently recommended evaluation of the feasibility of organised prostate cancer screening. In Sweden, regional population-based organised prostate cancer testing (OPT) programmes were introduced in 2020. To describe initial participation rates and diagnostic outcomes. The three most populated Swedish regions invited all men aged 50 yr to OPT by a letter in 2020–2022. Men with prostate-specific antigen (PSA) ≥3 ng/ml were referred for prostate magnetic resonance imaging (MRI). PSA assays differed across regions. Men with Prostate Imaging Reporting and Data System (PI-RADS) 1–3 and PSA density ≥0.15 ng/ml/cm3 or PI-RADS 4–5 were referred for a biopsy. Data were obtained from the Swedish Register for Organised Prostate Cancer Testing. Overall and regional participation rates, PSA distributions, PI-RADS score distributions, cancer detection, and treatment were evaluated. A total of 23 855 (35%) of 68 060 invited men participated; 696 (2.9%) had PSA ≥3 ng/ml, and of them, 306 (44%) had a biopsy indication and 221 (32%) had a biopsy. On biopsy, 93 (42%) had Gleason grade group ≥2 (0.39% of PSA-tested men) and 44 (20%) Gleason grade group 1 cancer. Most men with cancer had treatment with curative intent (70%) or were under active surveillance (28%). Across regions, proportions of men with PSA ≥3 ng/ml ranged from 2.3% to 4.0%, and those with PI-RADS score 4–5 ranged from 12% to 21%. A limitation is that results are applicable only to first testing of men in their early 50s. The OPT programmes are feasible with good compliance to the diagnostic pathway. The use of MRI and PSA density avoided a biopsy for over half of the men with PSA ≥3 ng/ml. Inter-regional differences in diagnostic outcomes show a need for standardisation of the diagnostic pathway's components. We report the diagnostic outcomes of inviting 68 000 50-yr-old men to organised prostate cancer testing.
Interim Results of the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma
Authors: Chunyan Sun, Baijun Fang, Guangxun Gao, Fuling Zhou, Aili He, Fei Zhao, Junying Li, Chun Zhang, Li Weiming, Hui Cheng, Huili Cai, Bin Chen, Jingming Guo, Yu Hu
Journal: Blood (2023)
Somatic Mutations in Cancer-Related Genes Were Observed More Frequently in AYA CML Patients Compared to Elderly at Diagnosis, Whereas the Frequency Was Markedly Higher in Elderly Patients during TKI Treatment
Authors: Jitka Krizkova, Vaclava Polivkova, Nikola Curik, Adam Laznicka, Adela Benesova, Hana Klamova, Marketa Stastna Markova, Dana Srbova, Jan Zuna, Marketa Zaliova, Jan Trka, Pavel Semerak, Tomas Kalina, Cyril Salek, Katerina Machova Polakova
Journal: Blood (2023)
Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy
Authors: Adam D. Cohen, Wei-Ting Hwang, Sandra Susanibar-Adaniya, Dan T. Vogl, Alfred L. Garfall, Adam Waxman, Danielle Zubka, Chau Nguyen, Cynthia Diaczynsky, Marco Ruella, Michael C. Milone, Edward A. Stadtmauer
Journal: Blood (2023)
CRISPR/Cas9 Strategy for Correcting <i>ELANE</i> Mutations and Restoring Neutrophil Differentiation in Severe Congenital Neutropenia: Insights from Patient-Derived iPSCs
Authors: Zuzanna Rydzynska, Dawid Grzela, Monika I Linder, Weronika Dobrewa, Zuzanna Urbanska, Bartlomiej Pawlik, Damian Krzyzanowski, Maciej Mazurek, Szymon Janczar, Joanna Madzio, Wojciech Mlynarski
Journal: Blood (2023)
Accomplices in Cure: Blinatumomab + Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion
Authors: Nora Philipp, Anetta Marcinek, Gerulf Hänel, Daniel Nixdorf, Veit L. Buecklein, Marion Subklewe
Journal: Blood (2023)
Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies
Authors: Tapan M. Kadia, Hagop Kantarjian, Gheath Alatrash, Anna Sergeeva, Hong He, Lisa St. John, Priya Koppikar, Celine Kerros, Karen Clise-Dwyer, Kathryn Ruissard, Abhishek Maiti, Courtney D. DiNardo, Elias Jabbour, Srdan Verstovsek, Naveen Pemmaraju, Nitin Jain, Ghayas C. Issa, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Aditi Shastri, Daniel R. Couriel, Maria Rhona Pinsoy, Sapna Parshottham, Richard E. Champlin, Jorge Cortes, Jeffrey J. Molldrem
Journal: Blood (2023)
A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)
Authors: Marie Anne Hospital, Thomas Cluzeau, Alice Garnier, Giovanni Marconi, Emmanuelle Tavernier, Sylvain Thepot, Aspasia Stamatoullas, Cristina Papayannidis, Sophie Park, Noemie Bigot, Lamya AIT SI Selmi, Fatiha Chermat, Sylvie Chevret, Pierre Fenaux
Journal: Blood (2023)
Bone Marrow Versus Peripheral Blood in HLA-Matched Sibling Transplantation: Does the Stem Cell Source Matter in Severe Aplastic Anemia?
Authors: Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Seung-Hwan Shin, Sung-Eun Lee, Byoung Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Jong-Wook Lee
Journal: Blood (2023)
Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The “Real World” Italian Experience
Authors: Michele Merli, Antonella Anastasia, Marina Deodato, Luca Nassi, Chiara Cavalloni, Silvia Franceschetti, Massimo Gentile, Annalisa Arcari, Roberto Sartori, Emanuele Cencini, Giacomo Loseto, Candida Vitale, Gioacchino Catania, Ombretta Annibali, Daniela Nasso, Federica Cocito, Isacco Ferrarini, Silvia Finotto, Alessandro Noto, Benedetta Bianchi, Andrea Ferrario, Marina Motta, Sara Rattotti, Annamaria Frustaci, Francesco Passamonti, Luca Arcaini
Journal: Blood (2023)
Epidemiology and Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A US Population-Based Study
Authors: Ujjwal Karki, Pravash Budhathoki, Anish Shah, Bipin Ghimire, Shyam K Poudel, Mohammad Muhsin Muhsin Chisti
Journal: Blood (2023)
Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients
Authors: Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee
Journal: Blood (2023)
Impact of Progression-Free Survival at 24 Months on Subsequent Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Supplementary Analysis of JCOG0601
Authors: Ayumi Fujimoto, Wataru Munakata, Gakuto Ogawa, Tomotaka Suzuki, Kazuyuki Shimada, Tsutomu Kobayashi, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Dai Maruyama, Hirokazu Nagai
Journal: Blood (2023)
Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens
Authors: Naszrin Arani, Emmanuel Almanza, Alex Bataller, Courtney D. DiNardo, Farhad Ravandi, Naval Daver, Naveen Pemmaraju, Musa Yilmaz, Abhishek Maiti, Patrick K Reville, Sanam Loghavi, Hussein A Abbas, Guillermo Garcia-Manero, Nicholas J. Short, Hagop M. Kantarjian, Tapan M. Kadia
Journal: Blood (2023)
Hairy Cell Leukemia with Severe Leukocytosis
Authors: Mohammed Almakadi, Muhammad Rehan Akram, Dalal Aldhafeeri, Ahmed Alrajjal, Ahmed Elazony, Azhar Nawaz, Mohammed Alruwaythi, Hamoud Althubyani, Amal Albeihany, Liju Ahmed
Journal: Blood (2023)
NCAPD3 Prompts Diffuse Large B-Cell Lymphoma Progression through Modulating SIRT1 Expression in H3K9 Monomethylation-Dependent Manner
Authors: Tiange Lu, Xiangxiang Zhou, Juan Yang, Yiqing Cai, Mengfei Ding, Xiaomin Chen, Zhuoya Yu, Xiaosheng Fang, Xin Wang
Journal: Blood (2023)
Trial in Progress: An Open Label Phase I/II, Multicenter Study Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a BCL-2 Inhibitor Combined with Azacitidine in Adults with Previously Untreated Acute Myeloid Leukemia Ineligible for Intensive Treatment
Authors: Ana Alfonso Pierola, Stephane De Botton, Jun Ho Jang, Victoria Campbell, Jenny O'Nions, Maria Calbacho, Annette L. Ervin-Haynes, Kristen Keagle, Aline Maillard, Maud Beneton, Mathilde Romagnoli, Alberto Broniscer
Journal: Blood (2023)
Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA)
Authors: Amer M. Zeidan, Pierre Fenaux, Xia Han, David A. James, Kamel Malek, Pedro Marques Ramos, Yasushi Miyazaki, Uwe Platzbecker
Journal: Blood (2023)
CD38 KO/CD38-CAR Human Primary Natural Killer Cells Enhance Cytotoxicity Against CD38-Expressing Primary Lymphoma, Leukemia, and Myeloma
Authors: Ella C Troy, Yasemin Sezgin, Marcelo De Souza Pereira, Joseph Caporale, Gregory K Behbehani, Justin Lyberger, Dean Anthony Lee, Meisam Naeimi Kararoudi
Journal: Blood (2023)
Beneficial Role of Erythrocyte Sphingosine 1-Phosphate in Preventing Renal Macrophage Polarization and Fibrosis through Combating HIF-1α-Dependent Creatine Phosphate Shuttle
Authors: Tingting Xie, Changhan Chen, Yiyan Wang, Zhenjiang Li, Benjamin C. Brown, Rodney E. Kellems, Weiru Zhang, Angelo D'Alessandro, Yang Xia
Journal: Blood (2023)
The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Authors: Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, Amy Zhang, Ibrahim Aldoss, Rawan Faramand, Noam E. Kopmar, Kaitlyn C Dykes, Nikeshan Jeyakumar, Simone E. Dekker, Vishal K Gupta, Mohamed Ahmed, Aaron C. Logan, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shabaz Malik, John Mathews, Paul Shaughnessy, Abdullah Ladha, George Yaghmour, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Ryan D Cassaday, Bijal D. Shah, Katharine Miller, Lori S. Muffly, Ahmed Galal, Stephanie B. Tsai, Bhagirathbhai Dholaria
Journal: Blood (2023)
Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)
Authors: Slavisa Ninkovic, Costas K. Yannakou, Nicholas Murphy, Rosemary Anne Harrup, Craig Wallington-Gates, Magdalena Sobieraj-Teague, M Hasib Sidiqi, Anish Puliyayil, Wojt Janowski, John Reynolds, Andrew Spencer, Hang Quach
Journal: Blood (2023)